Dr Reddy's Laboratories launches Zoledronic Acid Injection

04 Apr 2013 Evaluate

Dr Reddy’s Laboratories has launched Zoledronic Acid Injection (5 mg/100 mL), a therapeutic equivalent generic version of Reclast (zoledronic acid) Injection 5 mg/100 mL in the US market on April 03, 2013, following the approval by the United States Food & Drug Administration (USFDA) of Dr Reddy’s ANDA for Zoledronic Acid Injection (5 mg/100 mL).

Dr Reddy’s Zoledronic Acid Injection (5 mg/100 mL) is available in a single use vial for Intravenous Infusion. According to IMS Health, the Reclast brand had total US sales of approximately $355 million for the most recent twelve months ending February 2013.

Dr Reddy's is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.

Dr. Reddys Lab Share Price

1267.15 -7.90 (-0.62%)
08-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1795.30
Dr. Reddys Lab 1267.15
Cipla 1497.45
Zydus Lifesciences 924.35
Lupin 2071.35
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×